Madopar 100 mg/25 mg (levodopa/benserazide)

Madopar is a prescription oral medication combining levodopa and the decarboxylase inhibitor benserazide for the treatment of Parkinson's disease and related indications. The Madopar brand is developed and marketed by Roche, a Swiss pharmaceutical company, and the product is listed on Roche product pages as Madopar (levodopa + benserazide). (roche.com)

Packaging and product forms include dispersible tablets, hard capsules and prolonged-release forms; patient information and SmPC entries describe the 100 mg/25 mg formulation and note Roche as the company responsible for the product in multiple markets. The UK/EMC listings and patient leaflets show Madopar 100 mg/25 mg dispersible tablets supplied in amber glass bottles of 100 tablets. (medicines.org.uk)

Manufacturing and supply for Madopar are handled across several sites and partners: regional Roche affiliates (for example Roche Farma in Spain and Roche Singapore Pte. Ltd. for certain markets) are cited as manufacturers or marketing authorisation holders, and contract manufacturers/packagers such as Delpharm Milano are used for primary packaging or production in some approvals — therefore the product is produced in multiple countries depending on market and batch. (oladoctor.com)

In summary: the pictured bottle is Madopar 100 mg/25 mg (levodopa/benserazide) — a Roche product. The brand originates from Roche in Switzerland and is ultimately owned by the Roche Group (headquartered in Switzerland). Manufacturing and packaging occur in multiple countries via Roche’s regional affiliates and contract manufacturers, so country of manufacture depends on the specific batch and market. (roche.com)